Thermo Fishers Oncomine Dx target test receives expanded regulatory approval in Japan

Thermo Fisher’s Oncomine Dx target test receives expanded regulatory approval in Japan

08:53 EST 27 Feb 2019 | Compelo Medical Devices

The next-generation sequencing (NGS)-based multiplex companion diagnostic (CDx) test simultaneously evaluates patient tumor samples for biomarkers associated with targeted therapies for non-small cell lung cancer (NSCLC). Oncomine Dx

The post Thermo Fisher’s Oncomine Dx target test receives expanded regulatory approval in Japan appeared first on Compelo Medical Devices.

More From BioPortfolio on "Thermo Fisher’s Oncomine Dx target test receives expanded regulatory approval in Japan"